HLA Typing for Transplant Market: Growth, Size, Share, and Trends

Market Growth Outlook Summary

The global HLA typing for transplant market growth in terms of revenue was estimated to be worth $0.8 billion in 2023 and is poised to reach $1.1 billion by 2028, growing at a CAGR of 6.3% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Growth in the HLA typing for transplants market is mainly driven by factors such as the increasing number of transplantations worldwide, rising technological advancements in the field of HLA typing, and increasing public-private funding for target research activities. Moreover, government initiatives to promote organ donations increase the accessibility of transplant procedures, and commercialization high resolution HLA typing assay.

Attractive Opportunities in the HLA typing for transplants Market

To know about the assumptions considered for the study, Request for Free Sample Report

HLA Typing for Transplant Market Dynamics

Driver: Increasing number of transplant procedures globally

HLA matching provides numerous benefits in organ transplantation, including fewer rejection episodes, reduced immunosuppression, better graft function, and longer graft survival. The steady rise in the number of transplant procedures has increased the demand for timely and accurate HLA typing, thus bolstering the demand for instruments and kits.

• According to the United Network for Organ Sharing (UNOS), in the US, organ transplant procedures increased from 39,701 in 2019 to 42,800 in 2022.
• In the UK, kidney transplant procedures increased from 2,567 in 2020 to 3,192 in 2022 (Source: Global Observatory on Donation and Transplantation (GODT).
• According to the Australian Donation and Transplantation Activity Report 2022, the number of kidney organ transplant recipients in Australia increased by 11% from 2021 (1,173) to 2022 (1,224).

This growth in procedural volumes and patient pool will ensure a sustained demand for donor-recipient HLA profiling and compatibility testing to eliminate the risk of immune rejection.

Restraint: High costs of molecular tests used for HLA typing procedures

HLA typing procedures for histocompatibility tests are conducted through specialized molecular diagnostic platforms that consist of several advanced technologies, such as NGS instruments to achieve the desired process outcomes, reduce cycle times, and increase sample throughput. However, innovative diagnostic instruments require significant capital investments and extensive scientific validation for market commercialization. For instance, NGS is a novel platform that integrates device automation and microfluidics for high sample throughput and effective genomic detection. The demand for premium-priced NGS-based assays is limited due to the preference for affordable or low-priced non-molecular assay techniques for HLA typing in transplant diagnostic testing owing to budget constraints.

OPPORTUNITY: Technological shift from non-molecular serological assays to gene-based HLA profiling

Traditionally, the donor-recipient screening process was carried out through the serology-based assay technique before a transplantation procedure. However, gene-based histocompatibility testing procedures have recently been increasingly preferred over serology-based assays. Molecular assay requires less analysis time, provides higher sample throughput, offers easy handling of multiple samples in one run, and requires a smaller amount of patient samples than serological assay techniques, thus increasing the adoption of molecular assay technologies for HLA profiling in transplant donor  patients.

CHALLENGE: Significant gap between organ availability and demand

There is a; considerable shortage of organs from donors in comparison to the high demand for organ transplants. The increasing number of  waiting list of organ tranplants has become a vhalalneging factor for HLA typing for transplant market.

HLA Typing For Transplant Market Ecosystem

Prominent companies in HLA typing for transplant market include Thermo Fisher Scientific (US), Illumina, Inc. (US), QIAGEN (Germany), CareDX (US),F. Hoffmann-La Roche Ltd. (Switzerland),Bio-Rad Laboratories, Inc. (US), Immucor, Inc. (US),  and Luminex Corporation (US)

In 2022, reagents & consumables to dominate the HLA typing for transplant industry, product & Service.

Based on the product & service, the HLA typing for transplant market is segmented into reagents & consumables, instruments, and software & services. In 2022, the reagents & consumables accounted for the largest share of the HLA typing for transplants  market. The higher utilization and repeated use of reagents & kits in HLA  typing by diagnostic laboratories & transplant centers growing demand for identification of accurate HLA alleles are likely to drive the the growth of the reagents & consumables segment.

In 2022, the molecular assay technologies segment accounted for the largest share of the HLA typing for transplant industry, by technology.

The HLA typing for transplant market, by technology, is segmented into molecular and non-molecular assay technologies. In 2022, the molecular assay technologies segment accounted for the largest share of the HLA typing for the transplants market. Molecular techniques, such as PCR and NGS allow for high-resolution HLA typing, and   faster turnaround to analyze and identify multiple alleles at HLA loci in comparison to traditional serology technology are likely to support the growth of the segment.

In 2022, The independent reference laboratories end-user segment accounted for the largest share of the HLA typing for transplant industry

Based on end-user, the HLA typing for transplant market is segmented into hospitals & transplant centers, independent reference laboratories, and research laboratories & academic institutes. In 2022, independent reference laboratories accounted for the largest share of the HLA typing for the transplants market. The large share of this segment can be attributed to the presence of advanced molecular technology offering high-resolution HLA typing, the growing number of reference laboratories offering HLA service, strong emphasis of reference of laboratories on investments in advanced HLA typing equipment in the field of HLA typing.

In 2022, North America to dominate in HLA typing for transplant industry

The HLA typing for transplant market is segmented into North America, Europe, Asia Pacific, Latin America and Middle-East Africa. North America is expected to dominate during the forecast period, primarily due surge in transplant procesures, well establish healthcare infrastructure,  high adoption of advanced diagnostic technologies, favoriable reimbursement policy, and strong presence of key manufactures offering high resolution HLA typing assays.

To know about the assumptions considered for the study, download the pdf brochure

The HLA typing for transplant market is dominated by players such as Thermo Fisher Scientific (US), Illumina, Inc. (US), QIAGEN (Germany), CareDX (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US)

Scope of the HLA Typing for Transplant Industry:

This research report categorizes the HLA typing for transplant market to forecast revenue and analyze trends in each of the following submarkets:

By Product & Service

• Reagents & Consumables
• Instruments
• Software & Services

By Technology

• Molecular Assay Technologies
  • PCR-Based Molecular Assays
    • Real-time PCR
    • Sequence-specific Primer-PCR
    • Sequence-specific Oligonucleotide-PCR
    • Other PCR-based Molecular Assays
  • Sequencing-based Molecular Assays
    • Sanger Sequencing
    • Next-generation Sequencing
    • Other Sequencing-based Molecular Assays
• Non-molecular Assay Technologies

By Application

• Diagnostic Applications
  • Antibody Screening
  • Chimerism Monitoring
  • Others
• Research Applications

By Transplant Type

• Solid Organ Transplant
• Soft Tissue Transplant

By End User

• Independent Reference Laboratories
• Hospitals & Transplant Centers
• Research Laboratories & Academic Institutes

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle-East Africa

Recent Developments of HLA Typing for Transplant Industry

• In September 2023,  Omixon, Inc. (US) launched its NanoTYPE RUO Multiplex Human Leukocyte Antigen Amplification kit compatible with Oxford Nanopore’s MinION Platform.
• In November 2022, Illumina, Inc. (US)  opened a new state-of-the-art Solutions Center in Dubai for expanding genomics research in Middle East
• In March 2022, 021, Immucor, Inc. (US) launched MIA FORA NGS Express HLA Typing Software.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst